Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Nikola Čuřík"'
Autor:
Monika Jaruskova, Nikola Curik, Rajna Hercog, Vaclava Polivkova, Eliska Motlova, Vladimir Benes, Hana Klamova, Pavla Pecherkova, Petra Belohlavkova, Filip Vrbacky, Katerina Machova Polakova
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 36, Iss 1, Pp 1-17 (2017)
Abstract Background Through high-throughput next-generation sequencing of promoters of solute carrier and ATP-binding cassette genes, which encode drug transporters, we aimed to identify SNPs associated with the response to imatinib administered for
Externí odkaz:
https://doaj.org/article/50d802bfd6834c5e9b0ebd9a761a70af
Autor:
Pavel Burda, Jarmila Vargova, Nikola Curik, Cyril Salek, Giorgio Lucio Papadopoulos, John Strouboulis, Tomas Stopka
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0152234 (2016)
GATA-1 and PU.1 are two important hematopoietic transcription factors that mutually inhibit each other in progenitor cells to guide entrance into the erythroid or myeloid lineage, respectively. PU.1 controls its own expression during myelopoiesis by
Externí odkaz:
https://doaj.org/article/349c961479ad44418f687c747a8e1f17
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e87448 (2014)
CCCTC-binding factor (CTCF) can both activate as well as inhibit transcription by forming chromatin loops between regulatory regions and promoters. In this regard, Ctcf binding on non-methylated DNA and its interaction with the Cohesin complex result
Externí odkaz:
https://doaj.org/article/3479aeba3d50472eb8a86377b47560a4
Autor:
Nikola Čuřík, Adam Laznicka, Vaclava Polivkova, Jitka Křížková, Pavel Semerak, Eva Pokorna, Pavla Suchankova, Pavel Burda, Andreas Hochhaus, Kateřina Machová Poláková
Publikováno v:
HemaSphere, Vol 7, p e71557f0 (2023)
Externí odkaz:
https://doaj.org/article/f028e86716ee4bd0bfe0dfd27a8cb9cf
Publikováno v:
Kidney & Blood Pressure Research, Vol 38, Iss 1, Pp 142-155 (2014)
Background/Aims: Podocytes are typically cultured on collagen I; however, collagen I is absent from healthy glomerular basement membranes. Erythropoietin (EPO) is thought to protect podocytes in vivo. Here, we studied how various types of extracellul
Externí odkaz:
https://doaj.org/article/13ce23d619c54c939dbf489509ea7001
Autor:
Pavel Burda, Alzbeta Hlavackova, Vendula Polivkova, Nikola Curik, Adam Laznicka, Jitka Krizkova, Jiri Suttnar, Pavel Klener, Katerina Machova Polakova
Publikováno v:
Molecular Metabolism, Vol 88, Iss , Pp 102016- (2024)
Objective: A prominent, safe and efficient therapy for patients with chronic myeloid leukemia (CML) is inhibiting oncogenic protein BCR::ABL1 in a targeted manner with imatinib, a tyrosine kinase inhibitor. A substantial part of patients treated with
Externí odkaz:
https://doaj.org/article/5291343c15e94e9fb1424c43740d28fb
Publikováno v:
Kidney & Blood Pressure Research, Vol 38, Iss 1, Pp 142-155 (2014)
Background/Aims: Podocytes are typically cultured on collagen I; however, collagen I is absent from healthy glomerular basement membranes. Erythropoietin (EPO) is thought to protect podocytes in vivo. Here, we studied how various types of extracellul
Autor:
Nikola Curik, Vaclava Polivkova, Pavel Burda, Jitka Koblihova, Adam Laznicka, Tomas Kalina, Veronika Kanderova, Jana Brezinova, Sarka Ransdorfova, Dominika Karasova, Katerina Rejlova, Marina Bakardjieva, Daniela Kuzilkova, David Kundrat, Jana Linhartova, Hana Klamova, Cyril Salek, Pavel Klener, Ondrej Hrusak, Katerina Machova Polakova
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Somatic mutations are a common molecular mechanism through which chronic myeloid leukemia (CML) cells acquire resistance to tyrosine kinase inhibitors (TKIs) therapy. While most of the mutations in the kinase domain of BCR-ABL1 can be successfully ma
Externí odkaz:
https://doaj.org/article/8005ecfc126d4bfeaf825124b03f64ae
Autor:
Klara Srutova, Nikola Curik, Pavel Burda, Filipp Savvulidi, Giovannino Silvestri, Rossana Trotta, Hana Klamova, Pavla Pecherkova, Zofie Sovova, Jitka Koblihova, Tomas Stopka, Danilo Perrotti, Katerina Machova Polakova
Publikováno v:
Haematologica, Vol 103, Iss 12 (2018)
The fusion oncoprotein BCR-ABL1 exhibits aberrant tyrosine kinase activity and it has been proposed that it deregulates signaling networks involving both transcription factors and non-coding microRNAs that result in chronic myeloid leukemia (CML). Pr
Externí odkaz:
https://doaj.org/article/5a120df0b57040db90b998afc262735e
Autor:
Vaclava Polivkova, Peter Rohon, Hana Klamova, Olga Cerna, Martina Divoka, Nikola Curik, Jan Zach, Martin Novak, Iuri Marinov, Simona Soverini, Edgar Faber, Katerina Machova Polakova
Publikováno v:
PLoS ONE, Vol 11, Iss 5, p e0155959 (2016)
Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual case
Externí odkaz:
https://doaj.org/article/eec7181a37d04b6a995c86b77927b702